ET
Energy Transfer LP Common UnitsstockNYSE
Market OpenNov 16, 2026 10:48:07 AM EST
19.32USD-0.412%(-0.08)3,383,377
Pre-marketNov 16, 2026 9:20:30 AM EST
19.39USD-0.044%(-0.01)
ET Reddit Mentions by subreddit
Loading…
ET Mentions × sentiment
Loading…
ET Specific Mentions latest comments & posts
SHORTING JPM CYBER ATTACK potentially
Yes, Chase is down. Plaid's own status page says Chase "is currently experiencing downtime impacting all channels." That means every way of reaching Chase, including the app, online banking and outside apps linked to your accounts, which Plaid connects. Its notice went up about 18 minutes ago. Downdetector shows reports since 9:53 AM ET, and people on X say card transactions are failing. Chase itself hasn't said anything yet, and nobody has specifically confirmed ATMs either way, but with card authorizations failing I'd expect withdrawals to fail too.
I'll recheck every 10 minutes and message you only when something changes, like Chase confirming the outage, word on ATMs, or the fix. The watch shuts off once it's resolved, or at 7 PM ET at the latest.
sentiment -0.803
I like energy but not ET. Had it for years, but always traded in a narrow range and the dividend/return wasn't worth it.
Plus the MLP tax headache; I hate K-1's, and their package was always notoriously late.
sentiment -0.696
**HELUS**
**Trial design**
PARADIGM is Helus’ Phase 3 program testing HLP003 as an add-on treatment for adults with MDD whose antidepressants haven’t worked well enough.
The program has two pivotal studies. APPROACH reported results this morning. EMBRACE is still recruiting, and its topline data are due in Q4 2027. In APPROACH, patients got either two 16 mg doses of HLP003 or placebo, with the doses spaced three weeks apart.
A subset of patients also continue into EXTEND, a long-term extension study. It offers open-label dosing or re-dosing to non-responders and to those who relapse, and should finish in 2028.
Both Phase 3 studies measure their primary endpoint at Week 6: change in MADRS from baseline versus placebo. The main design difference is the comparators. APPROACH, today’s readout, compares 16 mg with inert placebo only. EMBRACE compares 16 mg with both an 8 mg dose and inert placebo.
APPROACH’s intent-to-treat population was 222 adults with moderate-to-severe MDD (MADRS of 24 or higher): 112 received HLP003 and 110 received placebo. Average baseline MADRS was 32.7 in the drug arm and 33.8 in the placebo arm. Everyone kept taking their usual antidepressant for the whole study.
About 21.6% of participants said they had used psychedelics before, which is a fairly high proportion. Recent use was grounds for exclusion.
**Efficacy**
According to Helus, two 16 mg doses of its deuterated psilocin given three weeks apart cut MADRS scores by a statistically significant and clinically meaningful amount compared with inert placebo. The mean difference at Week 6 was -7.6 points.
The benefit seems durable. HLP003 beat placebo by 7.0 points at Week 12. The effect also came on quickly: after one dose, the gap was already 5.0 points at Day 2.
At Week 6, 56.3% of HLP003 patients responded (MADRS down at least 50% from baseline), compared with 28.2% on placebo. Remission (MADRS of 10 or below) was 50.9% versus 18.2%. At Week 12, response was 45.5% versus 19.1%, and remission was 40.2% versus 15.5%.
These rates compare well with those of already-approved adjunctive treatments.
A placebo-adjusted drop of -7.6 at Week 6 is a solid result. It is close to the -8.1 seen at the same time point in Emerge, Definium Therapeutics’ Phase 3 MDD study, which reported over the summer. However, Emerge used a single dosing session and gave the drug as monotherapy. As always, comparisons across trials need to be made and read carefully.
The placebo arm improved far more in Helus’ study than in Definium’s: MADRS fell 11.9 points at Week 6, against 5.2 points in Definium’s Phase 3 at the same point. Two possible reasons are that Helus’ design is adjunctive and that it involved two dosing visits.
Helus also wraps much more non-drug support around treatment than developers such as Definium or Compass. It uses a support framework called EMBARK. Helus says EMBARK takes established evidence-based treatments (EBTs) and pairs them with psychedelic-assisted psychotherapies that have been shown to work. Definium, for comparison, stresses that it only monitors patients. In principle, Helus’ heavier support could lift the placebo arm somewhat, although that didn’t happen in HLP003’s Phase 2 trial.
Either way, separating from placebo by 7.6 points on the primary endpoint, even with a strong placebo response, is an efficacy win for Helus.
CEO Michael Halstead had told investors that Helus treats a 4–5 point difference as the benchmark, pointing to adjunctive antipsychotics. Today’s result clears that threshold easily.
**Safety**
The press release gave very little safety data, and what it did include raised concerns.
Helus said no new safety signals emerged and that the drug was generally well tolerated. It also disclosed three serious adverse events (SAEs) that were judged related to HLP003.
The stock fell steeply before the market opened. An 8am ET conference call then gave much more detail on the SAEs, which seemed to calm investors. Shares opened only slightly lower and had won back much of the premarket loss.
On the call, the company said one of the three treatment-related SAEs was a suicide attempt by a patient who had not responded to the drug. Chief Medical Officer Amir Inamdar said it happened 55 days after the second dose. The patient overdosed on their antidepressant medication, was hospitalized, and was later discharged.
The company classified the event as treatment-related. Even so, Inamdar said it does not amount to a suicidality signal for HLP003. In his view, a signal would need three things: a statistically disproportionate rate, a clear timing link between drug and event, and other possible causes ruled out.
To support this, he cited:
* the patient’s underlying MDD and history of previous suicide attempts
* the boxed suicidality warning on the background antidepressant
* the time that had passed between dosing and the event
* the absence of any signal on the Columbia Suicide Severity Rating Scale (C-SSRS)
Helus gave no details on the other two treatment-related SAEs, which were simply listed as “Depression.”
Inamdar also said the placebo arm had no SAEs, and only two patients dropped out because of adverse events.
Halstead was asked whether these safety results would affect talks with the FDA or the design of a future REMS. He answered that, in short, they would not.
**Competitive positioning**
Helus is aiming its deuterated psilocin at adjunctive use in MDD patients who haven’t responded adequately to standard antidepressants. It considers this a large patient group: wider than a treatment-resistant depression (TRD) label, but narrower than a full MDD label.
Helus is targeting an NDA submission in 2028. That timing could put its approval about a year after two psilocybin products reach the market: Compass’ for TRD and Usona’s for MDD. How HLP003 would stand out in that market is unclear.
Halstead preferred to compare HLP003 with the five atypical antipsychotics approved as add-on MDD treatments. He described them as giving only a small benefit while causing side effects such as weight gain, cardiometabolic problems, and movement disorders. In the Q&A, he said Spravato could serve as a broad reference point for pricing.
Deuteration is a standard way to secure exclusivity, for example through new chemical entity (NCE) status or through patents, for a drug that might otherwise not get it. Helus has used this approach. Deuteration can change a molecule’s pharmacokinetics, but there is little evidence that it substantially changes how a psychedelic behaves clinically in people.
Using psilocin, the active metabolite of psilocybin, may still bring some benefits, and Helus highlights them. The main one, according to the company, is that psilocin is given already in its active form. This skips the body’s conversion of psilocybin to psilocin, which Helus says can improve efficiency and lower the “drug load.”
Helus has not yet released data on how long patients take to be ready for discharge, either today or with its earlier Phase 2 results. Inamdar said on the call that these data were gathered and will be published later. He added that in the mid-stage trial, acute effects lasted roughly four to six hours. It is also unclear whether Helus’ more intensive psychological support will be a commercial burden or a selling point.
**Analysis**
On efficacy, today’s results are a success for Helus. HLP003 is also the first psychedelic analog to produce Phase 3 data.
Showing clear separation from placebo despite a strong placebo response is a decisive win. On safety, the situation looks less worrying than the press release alone made it seem.
Attention now moves to EMBRACE, Helus’ second and larger Phase 3 study, which compares 16 mg with 8 mg and inert placebo. If EMBRACE also separates from placebo, with similar efficacy and a clean safety profile, Helus would be well placed to file. Management said this morning that it will not file on APPROACH alone and still aims to submit the NDA in 2028.
The open question is competitive positioning. A 2028 submission could mean launching alongside a few other psychedelic depression treatments. Helus presents its adjunctive focus as an advantage, but competitors’ drugs may also end up being used as adjuncts.
The more urgent issue may be cash. Helus had just over $170M as of September 30, 2026, and announced no financing today, so it may need to raise money soon.
sentiment 0.996
Hey there, I can help you with this.
In short, yes, you would be eligible to receive the amount of cash shown in your vested balance. It appears this is your overall balance, so the full amount, based on the screenshot, should be yours. For information on vesting, distributions after employment ends, and related topics, we highly recommend reviewing the Summary Plan Description (SPD). Since your plan is with Fidelity, if the employer has provided us with the document, you can review it online by taking the steps below on NetBenefits.com:
1. Click the 3 dots next to your plan that says "Quick Links"
2. Choose "Plan Information and Documents"
3. Select "Summary Plan Description (SPD)"
If you don't need the cash, you do have choices. This link below highlights each choice you can consider.
[Considerations for an old 401(k)](https://www.fidelity.com/viewpoints/retirement/what-to-do-with-an-old-401k)
If you have further questions about your plan or something you see in the SPD, our Workplace Investing team is happy to assist. Associates are available Monday through Friday from 8:30 a.m. to midnight ET. Please say "401(k)" when prompted by the automated system to be connected to the right group.
[Contact Us](https://www.fidelity.com/customer-service/contact-us)
Are you familiar with the implications of withdrawing early from your 401(k)?
sentiment 0.915
**BanBet Created** ▲
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **NVDA** | $170.00 (above) | $157.50 | +7.9% | Sat 9:18 AM ET |
sentiment 0.250
Hi there, thanks for posting, and welcome to our sub.
We haven't received widespread reports of this particular issue. Are you still experiencing this when making the request? I noticed you did several troubleshooting steps, but as a final suggestion, I recommend uninstalling and then reinstalling the app.
If the issue persists, please get in touch with our Technical Support team to troubleshoot further. Associates are available Monday through Friday from 8:30 a.m. to 9:00 p.m. ET.
Please say "technical support" when prompted by the automated system to be connected to the right group.
[Contact Us](https://www.fidelity.com/customer-service/contact-us)
I also want to mention that every Workplace Plan is unique, so what may or may not be available by phone can vary by plan. When you called in, were you able to request a hardship withdrawal over the phone?
sentiment 0.963
Thank you for reaching out. I'm so sorry to hear about your situation.
Generally speaking, naming a spouse as the primary beneficiary and children as contingent beneficiaries is a common arrangement. However, everyone's estate planning needs are unique, so you may want to consult an estate planner or tax professional to determine whether your current setup aligns with your goals. We also offer estate planning tools to help:
[Fidelity estate planner](https://www.fidelity.com/calculators-tools/fidelity-estate-planner)
If you need to review or make beneficiary changes, you can use the page below.
[Beneficiaries (login required)](https://digitalservices.fidelity.com/navigate/ent-beneficiaries/?poe=fidcom)
Even when accounts are jointly owned, Fidelity should still be notified of the death so that account registrations and records can be updated appropriately. Our Life Events team can guide the surviving owner through any required steps and documentation. You can start the process online below, or, if you prefer, use the link on the page to call them.
[Notify Life Events](https://digital.fidelity.com/prgw/digital/journeys/loss/report-a-death)
Regarding the 401(k) plan beneficiary distributions, you will need to confirm with the plan administrator. If they are with us, our Workplace team can review beneficiaries with you. They are available Monday-Friday from 8:30 a.m. to 8:30 p.m. ET.
[Contact us](https://www.fidelity.com/customer-service/contact-us)
If you have further questions, let us know. We wish you and your family all the best. 🙏
sentiment 0.979
ET
sentiment 0.000
ET Money Ultimate SIP – Mid-Term: My experience since January 2024. Are the returns justified by its dynamic allocation strategy?
sentiment 0.649
Klamottenkauf ist nicht geteilt im WM. Jeder ET kauft für seine Kinder Klamotten, die er dann während seiner Betreuungszeit trägt. Meine Kinder haben einen vollkommen gefüllten Kleiderschrank an beiden Orten. Wenn Elternteile "gemeinsame" Ausgaben (gibt es wie erwähnt in der Regel nicht, aber OK) verweigern, macht sie entweder der andere oder man richtet mit dem Kindergeld ein gemeinsames Konto ein, von dem dann alles "gemeinsames", was das Kind betrifft, abgeht. Kinder sind immer eine massive finanzielle Belastung. Entweder durch Unterhaltszahlung oder durch Betreuung inkl. aller Anschaffungen und Kosten. Kommt ungefähr aufs gleiche raus.
sentiment 0.844
Es gibt sicherlich Fälle, wo halt dem kooperationsfeindlichen Elternteil das Aufenthaltbestimmungsrecht entzogen wird und das Kind bei den kooperationsbereiten Elternteil wohnt und den anderen besucht. Hier sind dann eben finanzielle Ausgleiche erforderlich, aber eben auch weil es sich der kooperationsunwillige ET es sich selbst zuzuschreiben hat. Da bin ich als Richter dann auch echt nicht kompromissbereit. Bei solchem Kindergeburtstag greife ich dann durch.
sentiment 0.527
Today is the 45 day since the end of the quarter, and the last day for investment managers( who manage more than 100m USD ) to submit a snapshot of their holdings.
I will be watching TCI and Valley Forge since they like to file on the last day, and I will be watching their holding of FICO (VF) and GE (TCI).
Deadline is 5.30pm ET (6.30am singapore)
sentiment 0.361
**BanBet Created** ▲
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **SPCX** | $165.00 (above) | $137.84 | +19.7% | Thu 2:19 AM ET |
sentiment 0.250
**BanBet Created** ▼ | **Record:** 0W - 4L
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **ASTS** | $28.93 (below) | $32.14 | -10.0% | Mon, Nov 23, 1:42 AM ET |
sentiment 0.250
\*\*Title:\*\* Nvidia stock steady as Jensen Huang reportedly weighs CEO comeback, Musk backs return
\*\*Author:\*\* Ines Ferré · Senior Business Reporter Sun, November 15, 2026 at 7:56 PM CST 2 min read 292 | \*\*Published:\*\* 2026-11-16
\*\*Source Link:\*\* [https://finance.yahoo.com/markets/article/nvidia-stock-steady-as-jensen-huang-reportedly-weighs-ceo-comeback-musk-backs-return-015644730.html](https://finance.yahoo.com/markets/article/nvidia-stock-steady-as-jensen-huang-reportedly-weighs-ceo-comeback-musk-backs-return-015644730.html)
\---
Nvidia (NVDA) stock futures were little changed on Sunday evening as investors digested a report that supporters of Jensen Huang are lobbying for his return to the AI chip giant following his abrupt resignation last week.
Huang has discussed returning as CEO with confidants, the Financial Times reported Sunday, citing people familiar with the matter. Huang resigned last week following reports of affairs, including one with a woman who was reportedly suspected of being a Chinese spy.
According to the report, a Huang supporter said that a "war room" of Silicon Valley executives was being assembled to lobby Nvidia's board to reinstate him, including by seeking support from the White House.
"Everyone that matters in tech outside the frontier labs loves Jensen," the person said, adding that Huang supported the effort.
Meanwhile, SpaceX (SPCX) and Tesla (TSLA) CEO Elon Musk has come out in support of Huang, writing on X last Friday, "A petition is underway to reinstate Jensen, and I'm signing it too."
On Saturday, Musk said, "Jensen drove supply chain brilliantly at Nvidia, but many of those deals were a handshake with Jensen, not a written contract. Without Jensen, at least some of those critical deals will be lost."
The push to bring Huang back comes days after the FT reported that Nvidia's board had approached Arm Holdings (ARM) CEO Rene Haas as it searches for a successor. Nvidia CFO Colette Kress is serving as interim CEO during the search.
Yorkville's Dan Ives said that while "no one individual can replace Jensen as CEO," any talk of "Jensen coming back to Nvidia is ridiculous in our view given the legal/Board/DC scrutiny/moral compass/China tentacles."
\### NVIDIA Corporation (NVDA )
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Huang abruptly stepped down Thursday following reports of alleged affairs with a former executive from Singapore-based Megaspeed, and also an Nvidia employee who reported directly to him.
Exactly one week earlier, Huang acknowledged being unfaithful to his wife but did not disclose how many affairs he had or identify those involved.
Recent reports have raised concerns about whether restricted semiconductors were being diverted to China and if sensitive US information had been sent to Beijing.
The developments have also sent shockwaves through the AI industry, where Nvidia has played a central role in building the ecosystem. The company has become a bellwether for the AI trade and has invested in key parts of the industry, including large language model development, energy, optics, and cloud providers.
Nvidia is scheduled to report quarterly results Tuesday after the bell, in what will be the company's first earnings call without Huang.
The stock declined more than 12% last week, closing below a $4 trillion market cap. At least 10 Wall Street analysts have downgraded the stock from Buy to Hold, with many citing, in part, increased scrutiny in Washington and succession uncertainty.
sentiment 0.582
**BanBet Created** ▲ | **Record:** 0W - 4L
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **SPY** | $775.00 (above) | $754.37 | +2.7% | Sat 12:11 AM ET |
sentiment 0.250
I posted this last Friday. Nov. 15 9:12PM ET $47.67. I made decent money trading SLV around $20. Buy 1,000 shares, sell when it goes up $1 and buy back when it goes down $1. How soon til SLV back at $20?
I keep missing out on buying opportunities. When should I stop missing out on these deals?
October 22, Monument Metals: Huge Market Dip, silver below $55!
October 23, Buy the Dip, Silver around $54,
October 29, Market Alert, Silver fell to just over $52, its lowest in nearly a year!
November 12. Huge Market Dip, silver sank near $50!
EDIT: Nov. 13 12:51PM ET Silver:$ 49.23**$ - 0.91**
sentiment 0.684
**BanBet Created** ▲
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **DRAM** | $45.00 (above) | $42.40 | +6.1% | Sun, Nov 22, 9:01 PM ET |
sentiment 0.250
**BanBet Created** ▼
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **QQQ** | $666.00 (below) | $676.95 | -1.6% | Mon 8:59 PM ET |
sentiment 0.250
Not sure why you'd have a commission, but whatever.
If you want the money ASAP, use a market order. Unless something crazy happens before 9:30 ET tomorrow morning, your order will get filled at \~$106 ish.
sentiment -0.482
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial; Conference Call Scheduled for 8:30am ET November 16 - DRTS DRTSW
sentiment 0.557
Fair, a gap fill before more downside fits what the tape is doing. The bounce has been weak so far: BTC is around 64,900, still below where it was 24 hours ago (about 65,670) and well under the 66,110 high from 4 AM ET. Funding on BloFin's BTC perp is basically flat at about +0.001% per 8h, so nobody is getting squeezed on the way up. A move back into the gap without funding flipping positive looks more like a relief bounce than a reversal to me.
sentiment 0.301
Most people I've seen split it. RTH (9:30-16:00 ET) as the main profile, since that's where most of the volume trades, and the overnight session as its own profile. Then the overnight high/low and the prior RTH value area are your levels for the open. A full 24h profile on NQ tends to blur the value area.
sentiment 0.586
| Ticker | Target | Entry | Current | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|:---:|
| **SPY** ▼ | $730.00 (below) | $750.39 | $754.37 | -2.7% | Fri, Nov 27, 12:05 PM ET |
| **Record** | 5W - 0L | 100% | - | - | - |
sentiment 0.000
Hey all.
Ever wonder why the same setup works great some days and gets chopped up on others? A lot of the time the difference is what the options board is doing underneath it. That’s what I built this to read.
Full disclosure, I built it and it's paid. It's called TRT Compass, a desktop app for Windows and Mac that reads the options board on your own ThetaData feed and says what it sees in plain words.
Here's QQQ on Thursday, about an hour apart, with the dollar sizes hidden. This is the Chart Room, Compass’s own charting, with the GEX ladder drawn right beside the candles so the size and the price sit on one screen. Watch only the ladder on the right. At 10:07 ET price is sitting on the biggest strike, 685, with only a little size above it. As the move starts, size keeps building above price and draining below it. The board was in AMPLIFY, where the hedging moves with price instead of leaning against it, and price only got sticky once it got up into that stack of positive strikes. By 11:23 the biggest strike had moved up to 700.
[QQQ, Thu 12 Nov, 10:07 ET. Price sitting on the King at 685, not much size above it yet. Dollar sizes hidden.](https://preview.redd.it/ejv27bocrs1i1.png?width=1486&format=png&auto=webp&s=1e9cfabda120454d51f9dd2fd91d0ea383c5e9bf)
Here's that read, and you can do it yourself with any options chain and a free GEX site. Three questions. Where does the biggest size sit? Is the board amplifying or compressing, meaning is the hedging chasing price or leaning against it? And as price moves, is size building in front of it or draining behind it? When it's amplifying and the size ahead keeps building, I stay with the move until price gets up into that size. That's mainly how I trade. I read QQQ and take the move on NQ, same with SPY and ES. Occasionally I'll still trade SPX options.
[Same board, 11:23 ET. Size built from 693 up to 705 as price moved into it, and the King moved to 700.](https://preview.redd.it/9ro0rlrdrs1i1.png?width=1486&format=png&auto=webp&s=738f6807e6059d18d177211c35009b0e5fa38549)
The hard part is answering those three live, on three boards at once, with your hand on the mouse. A GEX chart hands you 40 strikes of numbers and leaves the rest to you, and the rest is exactly the part you're worst at in the middle of a red candle. I know I was.
Compass does the interpretation and says it in words instead of just giving you rows of numbers. Here's the phone view on SPY the morning of 9 Nov, and these are lines straight off it: "752 not tested since Compass started." "The King changed hands 1 time." Next to every level it says how often price has actually gotten that far, "likely", "a stretch", "rarely reached", measured on our own recordings instead of calculated. And when the board is quiet it says that too, which ends up being one of the most useful lines on the screen.
[The mobile view on SPY, Mon 9 Nov, mid-morning.](https://preview.redd.it/m5yqiu2mrs1i1.png?width=2514&format=png&auto=webp&s=2f9947eef8afb6b9ad0a6174b75853b126d29927)
This one's from the Weekly King Book, every session drawn with where the biggest strike sat. Friday, QQQ opened over a 685 King, fell through it to 671.90, and once 680 took over, price walked up to it by about 2pm ET. The quiet days are in the book too.
[Weekly King Book, QQQ, Fri 13 Nov.](https://preview.redd.it/jcr1y9zurs1i1.png?width=1956&format=png&auto=webp&s=c17ef7586ccaffb61d43cd927e549708523c7ee5)
Then there's the swing side, the Telescope. Every night it reads open interest across every live expiry, weights the 8 to 30 day contracts the heaviest because that's where a swing actually lives, and makes the call in one line: the side if the board has one, the level carrying real size, how often price has gotten that far inside a week on our own recordings, and the level that ends the read. On a quiet board it says "A watch this week, not a position yet."
Here are the 21 beta boards that pass that rule. 13 reached their level, 6 hit their out, 2 ran out of time. We found that looking back, so the forward record is what counts. Held boards still get logged and graded the same way, and from 1.0 on every board that finishes gets published, the outs included, every Sunday on the TRT Compass X. That's the real test.
[The 21 beta swing boards that pass today's rule \(posted with the name's own 20-day average\), outs included.](https://preview.redd.it/rx9mw7uzrs1i1.png?width=2000&format=png&auto=webp&s=d985ffa889995b599c5c75ec01dd49ace96f19ff)
What every board has is the level that ends it, written the night before. That's the part I care about most. You decide where you're wrong while you're calm, with the board in front of you.
Why I built it. I was a neurologic OT for 8 years before I became a trader, and a big part of that job was watching what the brain does under load. I'd have someone do a task perfectly in a quiet room with me. Same person, same hands, then at home with the TV on and family in the room or all eyes on them and it fell apart. Their ability never changed... the load did. In OT the fix is changing the environment so the task asks less of them.
Trading is the same problem. The right side of a chart is empty and your brain fills that blank in. It draws the next few candles for you. "It's going to bounce." "It's going to break." Then real money goes on, your attention narrows onto the last candle, and the part of you that holds the plan gets quieter right when you need it. Compass is me changing the environment. The board is where the size actually sits, said in plain words, so there's less empty space for my head to fill.
The skeptic stuff... because I'd be asking too. Open interest shows where the size sits, and that’s exactly what Compass reads: where it is, how big, and how it’s changing. What held up on all our recordings was the environment and the distance. Across 1.5 years and three products, amplified boards covered about 1.8 times the ground compressed ones did, which is why the second question matters so much. And if you’re wondering about backfitting, Compass has officially recorded every session since August, every board is dated the night it posts, and the outs stay up. I’d rather you judge it on what it posts next than on anything I say about the past.
Cost, all in: $175 a month after a free first month, plus your own ThetaData Options Standard at $80 a month, paid to them, so about $255 a month. The $175 is the software plus help from me getting set up and whenever you get stuck. ThetaData is separate because of the data. It comes straight from ThetaData to your own computer, so the board updates every few seconds. A lot of GEX tools give you a snapshot every few minutes, and the few minutes right after price starts running are exactly when you need the read.
A few things are free on [trtcompass.com](http://trtcompass.com), no signup. The Legend has every word on the screen. The Today page posts how the boards opened just after 9:30 ET and how each session closed after 4:20. The Weekly King Book goes up on the TRT Compass X every week.
Now, I'm here and happy to answer any questions you have, the hard ones included.
Do you trade more intraday or swings?
sentiment 0.987